JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Adaptive Biotechnologies Corp

Suletud

17.18

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.18

Max

17.45

Põhinäitajad

By Trading Economics

Sissetulek

4.2M

-26M

Müük

6.4M

59M

Kasumimarginaal

-43.467

Töötajad

619

EBITDA

11M

-18M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

-7.08% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. nov 2025

Turustatistika

By TradingEconomics

Turukapital

1.1B

2.7B

Eelmine avamishind

17.18

Eelmine sulgemishind

17.18

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. okt 2025, 18:41 UTC

Tulu

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. okt 2025, 18:31 UTC

Tulu

Correction to Procter & Gamble to Focus on Innovation

24. okt 2025, 16:25 UTC

Suurimad hinnamuutused turgudel

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. okt 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. okt 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. okt 2025, 21:07 UTC

Tulu

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. okt 2025, 20:58 UTC

Tulu

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 20:40 UTC

Tulu

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. okt 2025, 20:24 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:23 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:13 UTC

Tulu

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. okt 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. okt 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. okt 2025, 19:33 UTC

Tulu

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. okt 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. okt 2025, 18:52 UTC

Tulu

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:41 UTC

Tulu

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:03 UTC

Tulu

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. okt 2025, 18:02 UTC

Tulu

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. okt 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. okt 2025, 16:57 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. okt 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. okt 2025, 16:44 UTC

Market Talk
Tulu

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. okt 2025, 16:39 UTC

Market Talk
Tulu

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. okt 2025, 16:33 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:23 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 16:07 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Adaptive Biotechnologies Corp Prognoos

Hinnasiht

By TipRanks

-7.08% langus

12 kuu keskmine prognoos

Keskmine 16 USD  -7.08%

Kõrge 20 USD

Madal 11 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Adaptive Biotechnologies Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

8.81 / 10.18Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
help-icon Live chat